Abstract Probiotics for the prevention of necrotizing enterocolitis have attracted a huge interest. Combined data from heterogeneous randomised controlled trials suggest that probiotics may decrease the incidence of NEC. However, the individual studies use a variety of probiotic products, and the group at greatest risk of NEC, i.e., those with a birth weight of less than 1000 g, is relatively underrepresented in these trials so we do not have adequate evidence of either efficacy or safety to recommend universal prophylactic administration of probiotics to premature infants. These problems have polarized neonatologists, with some taking the view that it is unethical not to universally administer probiotics to premature infants, whereas others regard the meta-analyses as flawed and that there is insufficient evidence to recommend routine probiotic administration. Another problem is that the mechanism by which probiotics might act is not clear, although some experimental evidence is starting to accumulate. This may allow development of surrogate endpoints of effectiveness, refinement of probiotic regimes, or even development of pharmacological agents that may act through the same mechanism. Hence, although routine probiotic administration is controversial, studies of probiotic effects may ultimately lead us to effective means to prevent this devastating disease.
Introduction
Although necrotizing enterocolitis (NEC) is one of the most common life-threatening surgical diseases affecting neonates, we still do not completely understand the pathogenesis, or how to prevent or treat the disease [1] . The mortality for surgical NEC remains high, at around 30 % [2, 3] , and although therapies such as stem cells provide some promise [4] , unless there is a major novel development, it is unlikely that improvements in the surgical or medical treatment of unstable infants with major gut necrosis will significantly reduce this mortality [5] . Survivors of acute NEC may have long-term morbidities related both to gut necrosis (e.g., short bowel syndrome [6] ) and systemic sequelae (e.g., adverse neurodevelopmental outcome [7] ). Given the morbidity and mortality and the lack of specific treatment, there is an urgent need for development of preventative strategies. A huge amount of interest and hope bordering on evangelism has been invested in the routine administration of probiotics to prevent or eradicate this disease. Neonatologists are quite polarized on the issue of probiotics to prevent NEC: proponents of probiotics regard the fact that probiotics are not routinely given to premature neonates as unethical, detractors regard the meta-analyses combining different probiotic strains as deeply scientifically flawed. The American Pediatric Surgical Association Outcomes and Clinical Trials Committee considered the level of evidence for routine probiotic supplementation and concluded that 'Substantial data support routine supplementation of enteral intake with probiotics in premature infants to reduce the incidence of severe NEC (Grade A/B). No formal recommendations regarding the formulation, timing or duration of supplementation could be determined, but at least one probiotic formulation initiated in the first week of life and continued for at least 2 weeks appears appropriate.' [8] . However, it was also noted in this review that 'No conclusions regarding probiotic use in ELBW (\1000 g) infants could be extrapolated from the studies due to limited data. ' The aims of this review article are to discuss the rationale for the administration of probiotics to prevent NEC, the scientific basis for their action, and briefly discuss the current evidence for effectiveness.
Pathogenesis of NEC
Although the pathogenesis of NEC is incompletely understood, there are several established risk factors, including prematurity, altered intestinal blood flow/oxygen delivery, formula (as opposed to human breast milk) feeding, immature immune responses and a bacterial component. While the precise role of bacterial agents in the development of NEC is unclear, several factors implicate their involvement. Occasionally NEC is observed to occur in clusters, in which a higher than expected number of cases are observed in one centre [9] . Identical organisms are grown from babies within these clusters and the initiation of infection control measures has been shown to control such outbreaks [10] . However, different organisms are grown from separate outbreaks so it cannot be claimed that a single organism is involved in development of NEC. Bacterial involvement in the pathogenesis of NEC is also implicated by association; endotoxemia [11, 12] and positive blood cultures are common in infants with NEC and the gastrointestinal pneumatosis found in NEC contains 30 % hydrogen [13] , a gas produced solely by bacterial metabolism. Recent work implicating bacteria in the pathogenesis of NEC has also come from studies suggesting that NEC can be predicted before onset of clinical symptoms by analysis of fecal volatile organic compounds, which are likely to originate from intestinal microbiota [14, 15] . However, colonisation of the neonatal intestine is a complex process, and before considering the impact of probiotic administration on the incidence of NEC, it is important to consider the microbiome of the premature infant.
The infant microbiome
The adult human harbours a rich and diverse microbial community. It is estimated that microbes in the human body collectively outnumber human cells by a factor of 10 to 1 and that they encode for 100-fold more unique genes than our own genome [16] . The vast majority of these microbes are found in the gastrointestinal tract which is estimated to contain more than 1000 prevalent bacterial species [17] . Intestinal bacteria and humans usually establish a mutual relationship with each other. This relationship is encapsulated by the word commensal which originates from the Latin cum mensa or 'sharing a table' [18] . In return for providing a stable environment that is rich in energy sources derived from ingested food, intestinal microbiota provide important functions such as nutrient acquisition and energy regulation by breaking down otherwise indigestible food [19] . They also play a number of protective roles which include: development of the intestinal epithelium; limitation of pathogen colonisation by competing for adherence to epithelial surfaces; production of antimicrobial compounds; and regulation of intestinal immune responses [20] . Our natural microbial community evolves with us and plays a significant role in both health and disease. Changes in our microbiome have been implicated in a range of pathological conditions from obesity to inflammatory bowel disease [21] [22] [23] .
The original belief (first hypothesised at the turn of the 20th century) that humans develop within a sterile uterine environment [24] has more recently been challenged by increasing evidence that the infants' initial inoculum can be provided by maternal transmission before birth [25] . Further evidence refuting the belief that an infant's intestine is sterile at birth comes from the recent identification of numerous microorganisms in meconium [26] . The early establishment of an infants' microbiota is very unstable [27] and is influenced by a number of factors [28] . The most important of these factors likely include the mode of delivery [29] and feeding type during the initial post-partum period [30] . Vaginally delivered babies acquire their mothers' vaginal flora at birth (by contrast, babies delivered by Caesarean section are colonised with bacterial communities resembling the skin) [29, 31] . Following initial inoculation, culture based studies suggest that aerobic species such as Enterobacteriaceae, staphylococci and streptococci become established early colonisers during the first 2-3 days and their presence creates an anaerobic environment which facilitates the growth of species such as Clostridia, Bacteroides and Bifidobacteria [32] . Breastmilk is an additional rich source of microbes [33] . By the end of the first week after birth, Bifidobacteria dominate the flora of breast fed infants with formula fed infants harbouring a more heterogeneous intestinal microbial community [34] . During infancy, a unique balance is formed by gastrointestinal microbes and host tolerance and diet, all of which influence the acquisition and eventual stability of the intestinal microflora [35] .
In preterm babies, the normal succession of bacterial colonisers may be interrupted by a variety of factors. Infants are usually nursed away from their mothers in the sterile and often hostile environment of the intensive care unit. Birth by caesarean section, broad spectrum antibiotic administration, delayed initiation of feeds and placement of invasive catheters can interrupt the process of normal colonisation and result in a more restricted enteric microbiota with delayed colonisation by Bifidobacteria [36, 37] . In contrast to term infants, the gastrointestinal tract of preterm babies lacks microbial diversity and frequently becomes colonised with limited numbers of bacterial flora. It is often dominated by potentially pathogenic species including: Enterobacteria, E. coli, Bacteroides, Enterococci, Streptococci, Staphylococci and Klebsiella [38, 39] . As a commensal microbiome is self-perpetuating [40] , so, similarly, is an abnormal microbiome, in the sense that a failure to establish a normal spectrum of commensals within the gut predisposes to further pathogenic colonisation. Abnormal pathogenic intestinal microbiomes are characteristically less diverse than normal gut flora [41] , and consequently do not induce the competitive environment which limits the influx of extrinsic pathogens. Similarly, the aforementioned homeostatic behaviour of commensal organisms (i.e., inflammatory dampening, induction of self-sustaining nutrition) is absent, leading to instability of the microbiome.
It has been suggested that the risk of developing NEC, (similar to other inflammatory bowel conditions like Chron's disease) is increased when the balance between pathogenic and commensal bacteria shifts in favour of the former resulting in an abnormal microbiome. This is facilitated through impairment of the natural barriers to bacterial translocation, creation of a pro-inflammatory milieu, and perpetuating an unstable microbiome, unfavourable to re-colonisation with commensals. Although no specific bacterial species have been associated with the development of NEC, studies have shown that the presence of some abnormal intestinal flora is associated with a greater risk of NEC [42] . Rather than a single causative agent, it is more likely that the composition or structure of the preterm intestinal bacterial community plays a role in disease development [43] . High throughput sequencing of bacterial flora from preterm infants shows that babies who develop NEC cluster separately from controls [44] . Furthermore, a close temporal relationship has been demonstrated between abnormal microbial colonisation patterns and NEC, with 'blooms' of pathogenic c-proteobacteria seen to precede the onset of clinical NEC by several days [45] . With the advent of modern pyrosequencing methods for microbiome analysis, we can expect more studies on the role of microbiota in the development of NEC. However, such data are very complex, and analysis of these data in a very heterogeneous disease like NEC is extremely challenging. Nevertheless, recent studies have suggested a loss in microbial diversity to occur immediately before NEC onset [46, 47] , with a consequent predominance of Escherichia spp. [46] or strict anaerobes [47] .
Probiotics for the prevention of NEC
In 1907, Nobel laureate Elie Metchnikoff proposed that yoghurt (containing probiotics) prolonged life [48] . The World Health Organisation defines probiotics as live organisms (bacteria and yeast) that, when ingested in sufficient amounts, have a beneficial effect on the overall health of the host [49] . Probiotics are derived from fermented foods, from beneficial commensals or from the environment and have been shown to act through diverse mechanisms from alteration of the commensal microbiota to modification of gut barrier function and intestinal immune responses [50] . Given their propensity for abnormal colonisation patterns, using probiotics to manipulate and potentially normalise the intestinal flora of preterm babies is an attractive therapeutic potential. This intervention might have particular relevance to diseases such as NEC where, changes in the gut microbial community preceding the onset of symptoms, has previously been demonstrated [44, 45] .
Proof of concept studies showing the ability of probiotic species to successfully colonise the preterm intestine began to emerge in the early 1990s [49] . Further evidence that probiotics might benefit preterm infants was reported by Kitajima and colleagues in 1997 who, in addition to demonstrating successful recovery of this probiotic from stool also reported that its administration was associated with a reduction in apnoea and vomiting [50] . In 1999, Hoyos and colleagues reported the outcome of a cohort study, in which, probiotic administration was associated with a reduction in the incidence of necrotizing enterocolitis [51] . Between 2003 and 2006, several randomised studies reported a reduction in the incidence of NEC among preterm babies recruited to probiotic trials (and receiving the probiotic intervention) though not all these studies were designed to evaluate NEC as a primary outcome [52] [53] [54] [55] [56] [57] . The first meta-analysis combining these results was published in 2007 and concluded that probiotics might reduce the risk of NEC in preterm babies born less 33 weeks gestation [58] . A further meta-analysis published by the Cochrane Collaboration in 2009 concluded that probiotics reduced the incidence of NEC in babies [1000 g birth weight [59] .
Despite these findings, enthusiasm for implementing the routine use of probiotics was hampered by numerous concerns. These concerns centred around the heterogeneity of probiotics used in individual studies, lack of data relating to optimum dosing and timing of intervention, short-and long-term safety of probiotics and perhaps most importantly, the lack of evidence for benefit among infants who might be deemed most at risk of developing NEC [60] [61] [62] and in particular those \1000 g. Additional concerns were raised about the quality of trials included in various meta-analyses. In 2012, Mihatsch and colleagues systematically analysed the level of evidence of published randomised controlled trials on probiotics in preterm babies in order to evaluate whether a statistically confirmatory basis could be provided to recommend routine probiotic use in very low birth weight babies (VLBW) to prevent NEC, sepsis, death and feeding tolerance. This study applied robust and validated methods to assess the quality of individual trials used in prior meta-analyses and reported that only 2 of 15 trials provided Level of Evidence (LoE) 1b neither of which supported the use of probiotics in preterm babies [63] . In the absence of confirmatory studies, many researchers agreed that a number of these concerns could only be addressed by further large randomised controlled trials.
In 2013, researchers from the University of Melbourne were the first to report the finding of the largest published neonatal probiotics trial to date [64] . This well-designed study addressed many of the previous concerns raised in relation to smaller trials and as such, the importance of this study cannot be understated. Most importantly, the authors reported a statistically significant reduction in NEC (Bell's stage 2 or 3) among infants born at \32 weeks gestation and randomised to receive a probiotic intervention containing three probiotic species. Infants who benefited most were those born at C28 week's gestation and C1000 g birthweight. However, NEC development was a secondary outcome to this trial, the primary outcome of which was late onset sepsis.
The results of further large trials recruiting a more appropriate target patient group are eagerly awaited. One such study (The UK-based PIPs trial) was designed with a primary outcome of sepsis, NEC or death, and recruited 1315 infants \31 weeks completed gestation [65] in England. This trial may provide further insight into the role of probiotics in the more immature preterm population.
The most recent updated Cochrane review on the use of probiotics in preterm babies includes more than 20 studies involving [5000 babies and includes data from the Australian ProPrems study. The reviewers conclude that enteral supplementation of probiotics prevents severe NEC and all-cause mortality in preterm babies [66] . But the evidence of benefit for babies born \1000 g birthweight (those babies deemed most at risk for NEC) remains less clear.
Safety of probiotics in preterm infants
Concerns about short-and long-term safety of using currently available probiotic interventions remain. Although some commentators have suggested that probiotic interventions should be considered separate to drug trials (because they are readily available as health supplements) [67] others have cautioned about the potential risks associated with their use [68] . Standard culture techniques do not reliably detect probiotic bacteria so sepsis due to probiotic micro-organisms may be under-reported. Hence, crucially, it cannot be concluded that probiotics are either effective or safe in the highest risk population. The case for addressing safety concerns is particularly important given the recent identification of Rhizopus oryzae in unopened probiotic containers and the death of a preterm baby from invasive fungal disease (http://www.fda.gov/Food/RecallsOut breaksEmergencies/Outbreaks/ucm423830.htm). The product implicated in this case is the same as that used in two previous randomised trials [54, 64] (one of which was the large Australian ProPREMS study) though neither of these groups reported any serious events during the course of their trials. Adverse events associated with using bacteria to manipulate the flora of premature babies have previously been described. During the 1960s numerous papers reported the efficacy of an apparent avirulent strain of Staphylococcus aureus 502A in aborting outbreaks of staphylococcal disease through the phenomenon of bacterial interference [69] . But the reported benefits were short-lived when the increasing use of this intervention was associated with the development of pustules in a high proportion of treated infants attributable to a mutated form of the bacteria [70] .
Mechanistic basic science studies on probiotics
One aspect that contributes to unease regarding clinical uptake of probiotics, but might ultimately help to define a product, is the lack of mechanistic understanding of how probiotics might prevent NEC. The literature on potential mechanisms of probiotic action is mainly from experimental models. Although there are various experimental models of NEC, and several have been used to examine the effects of probiotics in NEC, none seem to completely recapitulate the human condition [71] . Data from a clinically relevant model (spontaneous NEC in premature pigs) hint as to why routine introduction of probiotics is less than straightforward. In 2 separate studies, by the same group, divergent results were obtained [72, 73] . In one study, probiotics decreased severity of NEC lesions (but did not affect incidence) [72] , whereas in the other, probiotics significantly increased the incidence and severity of NEC [73] . These differing results illustrate in a microcosm the multifactorial and unpredictable nature of NEC and why we might not always expect consistent effects from probiotic administration to premature infants with very different microbiota.
A general assumption is that probiotics may reduce the incidence of NEC by altering the gut microbiome in favour of a more 'friendly' population of bacterial species which in turn reduces the risk of NEC. However, alteration of gut flora is only one potential mechanism by which probiotics might prevent NEC. Other mechanisms include effects on the gut immune system and via TLR-related signalling [74, 75] and effects on mucosal integrity and intestinal permeability [76, 77] . However, whether these are primary or secondary effects is extremely difficult to dissect, as the microbiome, immune system, mucosal integrity and gut barrier function are all mutually interdependent. Mechanistic studies in human infants are clearly difficult, but the group of Walker and Nanthakumar [78] has established protocols using immature human intestine that provides mechanistic insights. In one of these, intestinal tissue from therapeutic terminations of pregnancy is implanted in immune-deficient mice, the xenografts allowed to mature for 20 or 30 weeks to model immature intestine (i.e., susceptible to NEC) or mature intestine, respectively, and then challenged with inflammatory stimuli. In addition, enterocytes were isolated from resected ileum of an infant with NEC. Using these model systems, probiotic bacteria decreased inflammation, but, intriguingly, these effects could be reproduced by a small soluble factor produced by the probiotic bacteria. These data are supported by further studies which suggest that soluble factors secreted by Bifidobacterium infantis and Lactobacillus acidophilus are effective in preventing enterocyte damage [79, 80] . If this soluble factor(s) were to be identified, it might be possible to use this factor pharmacologically for NEC prophylaxis, which may be easier to get accepted into routine clinical practice than a potpourri of probiotics. Intriguingly, it has recently been suggested that the bacterial DNA alone of the probiotic strain Lactobacillus rhamnosus HN001 is sufficient to protect against NEC in a mouse model via activation of the TLR9 pathway [81] . A greater mechanistic understanding of the actions of probiotics may also allow development of surrogate endpoints of effectiveness, and refinement of probiotic regimes, as well as development of pharmacological agents.
Prebiotics and synbiotics
Other terms which have been used in connection with prevention of NEC, although neither are well researched, are 'prebiotics' and 'synbiotics'. Prebiotics are essentially dietary fibre, i.e., complex carbohydrates that are not readily digestible, but that are digestible by probiotic micro-organisms. Synbiotics are products that contain both prebiotics and probiotics, where the prebiotic acts synergistically as a substrate for the administered probiotic. Thus either prebiotics alone or synbiotics could also have beneficial effects on the microbiome of the premature infant. The only RCT addressing whether prebiotics or synbiotics can prevent NEC in premature infants showed that the rate of NEC was lower in pro-and syn-biotic supplemented infants than in prebiotic supplemented or control infants. There was no evidence to support a benefit of synbiotic over probiotic supplementation [82] .
Other concepts
Whilst the focus of scientific attention to date has been on the primary prevention of NEC by the use of probiotics, there are other related clinical scenarios in which there could be rationale for probiotic administration. One such scenario is following an episode of NEC since there is the potential for the use of probiotics after an episode of NEC to reduce the incidence of recurrent disease. Typical treatment for NEC includes 5-10 days 'nil-by-mouth' with administration of broad spectrum antibiotics, after which enteral feeds are cautiously re-introduced. A proportion of these infants go on to experience further episodes of NEC. Whilst it is not clear how many infants with early NEC experience recurrent episodes, approximately 10 % of infants with advanced NEC have recurrence [18] . This period of refeeding following a period of antibiotic 'cleansing' may provide an opportunity to use probiotics to redress the balance of the intestinal microbiome in favour of 'friendly' bacteria, and possibly decrease the incidence of recurrent NEC. To our knowledge, there have been no studies to date that have examined this issue; such initial studies would necessarily have a primary aim of safety.
Conclusions
There is no doubt that the use of probiotics offers an exciting potential to reduce important complications of prematurity including NEC but no studies to date have been conducted that can causally link clinical improvements to probiotic induced changes in the microbiota. We know that NEC is a complex disease, and that the intestinal microbiome is extremely intricate. Maybe the message from the sometimes confusing meta-analyses and RCTs is that we are being a little naïve in expecting a single probiotic to work like a drug, when it is in fact quite a complicated intervention. It is possible that providing a balanced mixture is beneficial-a parallel can be made with the ability of fecal microbiota transplantation to prevent recurrent C. difficile infection. Ongoing randomised studies underpinned by studies of mechanistic action and robust long-term follow-up are needed to address the many important unanswered questions that remain, that include (1) which probiotic strains to use?; (2) when to administer?; (3) who will benefit; and (4) who might we harm.
